Market Research Report
Short Bowel Syndrome Market - Growth, Trends, and Forecast (2020 - 2025)
|Published by||Mordor Intelligence LLP||Product code||922071|
|Published||Content info||110 Pages
Delivery time: 2-3 business days
|Short Bowel Syndrome Market - Growth, Trends, and Forecast (2020 - 2025)|
|Published: January 1, 2020||Content info: 110 Pages||
The Short Bowel Syndrome (SBS) Market studied was anticipated to grow with a CAGR of nearly 29.8%, during the forecast period. The major factors attributing to the growth of the SBS market are rise in global prevalence of GI disorders like volvulus, Inflammatory bowel disease (IBD), in particular, Crohn's disease (CD), which predisposes patients to development of SBS and mesenteric ischemia, which are the most common causes for SBS among all the age groups which demand the necessity of the treatment. For instance, in 2015, according to CDC, about 3 million adults of the United States were diagnosed with IBD which is a major cause of SBS. Additionally, the increased awareness programs led by several associations like the Association of gastrointestinal motility, Oley Foundation and the SBS Cure Project coupled with rising in the government health care expenditure are likely to drive the market growth over the forecast period.
Short bowel syndrome (SBS) is a metabolic disorder that occurs due to the malfunctioning or removal of the small intestine through surgery due to digestive illness. The consequences may be malabsorption, diarrhea, steatorrhea, fluid and electrolyte disturbances, and malnutrition. Short bowel syndrome is detected in Crohn's disease, radiation enteritis, and mesenteric ischemia. If left untreated, SBS can lead to complications such as anemia and kidney stones.
GLP-2 Drug Therapy by Drug Class is Expected to Hold the Largest Market Share in the Short Bowel Syndrome Market
North America Dominates the Market and Expected to do Same in the Forecast Period.
North America is expected to dominate the overall SBS market, throughout the forecast period. This dominance is mainly due to the revenue generated by the Gattex, the only glucagon-like peptide-2 (GLP-2) analog approved that improves intestinal absorption in patients with SBS in the U.S. Also, rise in the sedentary lifestyle that led no time to focus on nutritious and healthy food with increased consumption of unhealthy and junk food, resultant intestinal disorders are a major factor that drives the market growth in the region.
Europe is the second most prominent region in the global SBS market, which is due to research grants by the public & private players in the European countries to fuel the R&D of SBS drugs. Also, rapid approval of drugs like Revestive to treat SBS by the European Medical Agency is expected to drive the market growth in the region and propel the global market revenue.
The Asia Pacific is anticipated to grow at the fastest rate during the forecast period. It is due to the huge patient pool in China and India, and the uncontrolled consumption of antibiotics in India. Also, the research activities and investments on R&D in the region are estimated to fuel the growth of the SBS market in the Asia Pacific and attribute to a significant share in the global market.
The global short bowel syndrome market is moderately competitive and consists of several prominent industry players. Some prominent players are making partnerships and acquiring the blockbuster products in the market, other companies and expanding their market position globally. For instance, Takeda acquired the Shire, to expanding its geographic footprint and to be a leader in providing targeted treatments in gastroenterology, the leading companies in gastroenterology (GI) and neuroscience. While other key players are focusing on distributing and manufacturing of over-the-counter dietary supplements. Whereas, some companies such as Naia Pharmaceuticals SBS, Micelle BioPharma, Inc. are having new products in their pipeline. Some of the companies which are currently dominating the market are TAKEDA Inc, Naia Pharmaceuticals Inc, VectivBio AG, OxThera Inc, and Nutrinia Inc.